RecruitingPhase 2NCT06563323

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum

Sponsor

Oregon Health and Science University

Enrollment

17 participants

Start Date

Feb 1, 2025

Study Type

INTERVENTIONAL

Conditions

Pyoderma Gangrenosum Wound Heal Skin Diseases Skin Ulcer Pyoderma

Summary

A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Guselkumab for people with pyoderma, pyoderma gangrenosum, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.